389 related articles for article (PubMed ID: 23832510)
1. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.
Cinar R; Godlewski G; Liu J; Tam J; Jourdan T; Mukhopadhyay B; Harvey-White J; Kunos G
Hepatology; 2014 Jan; 59(1):143-53. PubMed ID: 23832510
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling.
Liu J; Godlewski G; Jourdan T; Liu Z; Cinar R; Xiong K; Kunos G
Hepatology; 2019 Apr; 69(4):1535-1548. PubMed ID: 30506571
[TBL] [Abstract][Full Text] [Related]
3. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.
Liu J; Zhou L; Xiong K; Godlewski G; Mukhopadhyay B; Tam J; Yin S; Gao P; Shan X; Pickel J; Bataller R; O'Hare J; Scherer T; Buettner C; Kunos G
Gastroenterology; 2012 May; 142(5):1218-1228.e1. PubMed ID: 22307032
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption.
Ussher JR; Koves TR; Cadete VJ; Zhang L; Jaswal JS; Swyrd SJ; Lopaschuk DG; Proctor SD; Keung W; Muoio DM; Lopaschuk GD
Diabetes; 2010 Oct; 59(10):2453-64. PubMed ID: 20522596
[TBL] [Abstract][Full Text] [Related]
5. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance.
Ussher JR; Folmes CD; Keung W; Fillmore N; Jaswal JS; Cadete VJ; Beker DL; Lam VH; Zhang L; Lopaschuk GD
PLoS One; 2012; 7(5):e37703. PubMed ID: 22629445
[TBL] [Abstract][Full Text] [Related]
7. CB
Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
Elife; 2020 Nov; 9():. PubMed ID: 33210603
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide Biosynthesis.
Teng W; Li Y; Du M; Lei X; Xie S; Ren F
Nutrients; 2019 May; 11(5):. PubMed ID: 31137828
[TBL] [Abstract][Full Text] [Related]
9. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.
Tam J; Szanda G; Drori A; Liu Z; Cinar R; Kashiwaya Y; Reitman ML; Kunos G
Mol Metab; 2017 Oct; 6(10):1113-1125. PubMed ID: 29031713
[TBL] [Abstract][Full Text] [Related]
10. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of central de novo ceramide synthesis restores insulin signaling in hypothalamus and enhances β-cell function of obese Zucker rats.
Campana M; Bellini L; Rouch C; Rachdi L; Coant N; Butin N; Bandet CL; Philippe E; Meneyrol K; Kassis N; Dairou J; Hajduch E; Colsch B; Magnan C; Le Stunff H
Mol Metab; 2018 Feb; 8():23-36. PubMed ID: 29233519
[TBL] [Abstract][Full Text] [Related]
12. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.
Tam J; Cinar R; Liu J; Godlewski G; Wesley D; Jourdan T; Szanda G; Mukhopadhyay B; Chedester L; Liow JS; Innis RB; Cheng K; Rice KC; Deschamps JR; Chorvat RJ; McElroy JF; Kunos G
Cell Metab; 2012 Aug; 16(2):167-79. PubMed ID: 22841573
[TBL] [Abstract][Full Text] [Related]
13. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.
Osei-Hyiaman D; Liu J; Zhou L; Godlewski G; Harvey-White J; Jeong WI; Bátkai S; Marsicano G; Lutz B; Buettner C; Kunos G
J Clin Invest; 2008 Sep; 118(9):3160-9. PubMed ID: 18677409
[TBL] [Abstract][Full Text] [Related]
14. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
[TBL] [Abstract][Full Text] [Related]
15. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide.
Watt MJ; Barnett AC; Bruce CR; Schenk S; Horowitz JF; Hoy AJ
Diabetologia; 2012 Oct; 55(10):2741-2746. PubMed ID: 22854889
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of the serine palmitoyltransferase subunit SPTLC2 by endoplasmic reticulum stress inhibits the hepatic insulin response.
Kim GT; Devi S; Sharma A; Cho KH; Kim SJ; Kim BR; Kwon SH; Park TS
Exp Mol Med; 2022 May; 54(5):573-584. PubMed ID: 35513574
[TBL] [Abstract][Full Text] [Related]
17. CerS1-Derived C
Turpin-Nolan SM; Hammerschmidt P; Chen W; Jais A; Timper K; Awazawa M; Brodesser S; Brüning JC
Cell Rep; 2019 Jan; 26(1):1-10.e7. PubMed ID: 30605666
[TBL] [Abstract][Full Text] [Related]
18. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation.
Jeon S; Scorletti E; Dempsey J; Buyco D; Lin C; Saiman Y; Bayen S; Harkin J; Martin J; Hooks R; Ogretmen B; Argemi J; Melo L; Bataller R; Carr RM
Mol Metab; 2023 Dec; 78():101804. PubMed ID: 37714377
[TBL] [Abstract][Full Text] [Related]
19. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.
Turpin SM; Nicholls HT; Willmes DM; Mourier A; Brodesser S; Wunderlich CM; Mauer J; Xu E; Hammerschmidt P; Brönneke HS; Trifunovic A; LoSasso G; Wunderlich FT; Kornfeld JW; Blüher M; Krönke M; Brüning JC
Cell Metab; 2014 Oct; 20(4):678-86. PubMed ID: 25295788
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
